{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T06:59:24Z","timestamp":1779260364291,"version":"3.51.4"},"reference-count":26,"publisher":"Korea Disease Control and Prevention Agency","issue":"6","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ophrp.org"],"crossmark-restriction":true},"short-container-title":["PHRP"],"published-print":{"date-parts":[[2024,12,31]]},"abstract":"<jats:p>Objectives: The aim of this study was to disseminate information about the safety of bivalent coronavirus disease 2019 (COVID-19) mRNA booster vaccines administered to adults in the Republic of Korea.Methods: Two databases were used to assess the safety of COVID-19 booster doses of Pfizer BA.1, Pfizer BA.4\/5, Moderna BA.1, and Moderna BA.4\/5 vaccines for adults aged 18 years and older. Adverse events (AEs) were analyzed using data reported to the web-based COVID-19 vaccination management system (CVMS) and a self-reported text-message survey.Results: Between October 11, 2022 and March 30, 2023, the CVMS received reports of 2,369 (93.7%) non-serious AEs from vaccinated adults, along with 158 (6.3%) serious AEs, which included 5 cases of anaphylaxis and 33 deaths. From October 11, 2022 to January 27, 2023, 40,022 people aged 18 and older responded to a survey conducted via text message. The booster doses were associated with fewer local and systemic AEs compared to the original vaccines. After receiving the bivalent vaccine, the most commonly reported AEs were pain at the injection site, headache, fatigue, and myalgia.Conclusion: Overall, bivalent vaccines exhibited fewer AEs compared to the original vaccines. The majority of AEs were non-serious, and serious AEs were rare among adults aged 18 years and older following vaccination with the Pfizer and Moderna bivalent vaccines.<\/jats:p>","DOI":"10.24171\/j.phrp.2024.0194","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T07:24:56Z","timestamp":1731396296000},"page":"542-549","update-policy":"https:\/\/doi.org\/10.24171\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety of the bivalent COVID-19 mRNA booster vaccination among persons aged over 18 years in the Republic of Korea"],"prefix":"10.24171","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6366-0987","authenticated-orcid":true,"given":"Seok-Kyoung","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7239-6353","authenticated-orcid":true,"given":"Seontae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6810-3079","authenticated-orcid":true,"given":"Mijeong","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2164-2737","authenticated-orcid":true,"given":"Yeseul","family":"Heo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2687-1405","authenticated-orcid":true,"given":"Tae Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4411-0941","authenticated-orcid":true,"given":"Yeonkyeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5767-1963","authenticated-orcid":true,"given":"Juyeon","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9053-1704","authenticated-orcid":true,"given":"Eunok","family":"Bahng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"31909","reference":[{"key":"ref1","volume-title":"Press releases: 70% of the people have been vaccinated, setting the stage for phased daily recovery (October 23, 2021, regular briefing) [Internet]","year":"2021"},{"key":"ref2","volume-title":"Press releases: response measures to block domestic inflow of COVID-19 Omicron variant (November 27, 2021, regular briefing) [Internet]","year":"2021"},{"key":"ref3","volume-title":"Press releases: bivalent vaccine for adults over 18 years of age (October 26, 2022, regular briefing) [Internet]","year":"2022"},{"key":"ref4","volume-title":"First adapted COVID-19 booster vaccines recommended for approval in the EU [Internet]","year":"2022"},{"key":"ref5","volume-title":"ECDC-EMA statement on booster vaccination with Omicron adapted bivalent COVID-19 vaccines [Internet]","year":"2022"},{"key":"ref6","volume-title":"Adapted vaccine targeting BA.4 and BA.5 Omicron variants and original SARS-CoV-2 recommended for approval [Internet]","year":"2022"},{"key":"ref7","volume-title":"Press releases: vaccination with BA.4\/5-based bivalent vaccine began on November 14th (November 10, 2022, regular briefing) [Internet]","year":"2022"},{"key":"ref8","volume-title":"Press releases: additional COVID-19 vaccinations in winter and strengthen the response system to infectious diseases at public health centers (September 21, 2022, regular briefing) [Internet]","year":"2022"},{"key":"ref9","volume-title":"Press release: Moderna bivalent vaccine approved for Omicron mutation (BA.1) [Internet]","year":"2022"},{"key":"ref10","volume-title":"Press release: Pfizer\u2019s Omicron variant (BA.4\/5) response bivalent vaccine approved for emergency use [Internet]","year":"2022"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00123-2"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.24171\/j.phrp.2021.0310"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.24171\/j.phrp.2022.0122"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.24171\/j.phrp.2022.0233"},{"key":"ref15","volume-title":"Guideline for adverse events following COVID-19 immunization [Internet]. 2-2nd ed","year":"2022"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7231a4"},{"key":"ref17","volume-title":"COVID-19 vaccination safety report (week 108)) [Internet]","year":"2023"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7144a3"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7223a2"},{"key":"ref20","volume-title":"ACIP presentation slides: September 1-2, 2022 meeting [Internet]","year":"2022"},{"key":"ref21","volume-title":"Overview of COVID-19 Vaccines [Internet]","year":"2024"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7202a5"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00054-8"},{"key":"ref24","volume-title":"COVID-19 vaccine safety data [Internet]","year":"2024"},{"key":"ref25","volume-title":"Press release: Ministry of Food and Drug Safety promotes rapid domestic introduction and supply of monovalent vaccine in response to COVID-19 Omicron submutation (XBB 1.5) [Internet]","year":"2023"},{"key":"ref26","volume-title":"Press release: Ministry of Food and Drug Safety approves emergency use of Moderna\u2019s vaccine against COVID-19 (XBB 1.5) [Internet]","year":"2023"}],"container-title":["Osong Public Health and Research Perspectives"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ophrp.org\/upload\/pdf\/j-phrp-2024-0194.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/ophrp.org\/journal\/view.php?doi=10.24171\/j.phrp.2024.0194","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/ophrp.org\/upload\/pdf\/j-phrp-2024-0194.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T06:48:26Z","timestamp":1735541306000},"score":1,"resource":{"primary":{"URL":"http:\/\/ophrp.org\/journal\/view.php?doi=10.24171\/j.phrp.2024.0194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"URL":"https:\/\/doi.org\/10.24171\/j.phrp.2024.0194","relation":{},"ISSN":["2210-9099","2233-6052"],"issn-type":[{"value":"2210-9099","type":"print"},{"value":"2233-6052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,31]]},"assertion":[{"value":"2024-07-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-29","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-31","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}